Paolo Cravedi

38PUBLICATIONS
105CO-AUTHORS
Molecular medicineCancer therapy (excl. chemotherapy and radiation therapy)HaematologyAvionicsImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (38)

|Apr 15, 2026
Dual anti-CD20/anti-CD38 therapy for severe recurrent FSGS with longitudinal anti-nephrin assessment.

Xhuliana Kajana, Agnese Spennacchio, Francesca Chiara Viazzi

|Mar 03, 2026
Can low serum complement be used as an indicator of thrombotic microangiopathy in kidney transplant candidates with unknown diagnosis?

Alessandra Palmisano, Micaela Gentile, Marta D'Angelo

|Oct 20, 2025
AI Will Offer New Opportunities for Transplantation: Are We Ready?

Umberto Maggiore, Jamil Azzi, Leonardo V Riella

|Aug 28, 2025
Complement and IgM in FSGS: Minor Characters or Leading Actors?

Andrea Angeletti, Paolo Cravedi

|Jul 15, 2025
Not all alloantibodies are created equal: IgG glycosylation and severity of antibody-mediated rejection in kidney transplantation.

Johan Noble, Leandre M Glendenning, Celine Dard

Pageof 7